Valuation dashboard for REGENXBIO Inc. (RGNX) with P/E N/A, P/B 5.87, EV/EBITDA -3.56 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Analysis Summary
REGENXBIO Inc. reported revenue of $170.4M in the most recent fiscal year, growing at a 5-year CAGR of 2.0%.
Trailing-twelve-month margins: gross margin 54.2%, operating margin -94.1%, net margin -112.6%.
At the current price of $7.98, RGNX has negative trailing earnings (P/E not meaningful) and an ROE of -220.07%. Market capitalisation stands at $413M.
Balance sheet quality for RGNX: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.87 |
| EV / EBITDA | -3.56 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-24.47 |
| vs Current Price | -406.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $413M | 5.87 | -220.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $7.98 |
| Market Cap | $413M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -220.07% |
| Return on Invested Capital | -52.72% |
| Return on Assets | -50.81% |
| Gross Margin | 54.22% |
| Operating Margin | -94.08% |
| Net Margin | -112.58% |
Related companies: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explore sector: Healthcare · Biotechnology
More sections of RGNX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks